 |
|
Cell skeleton may hold key to overcoming drug resistance in cancer
October 04, 2007Researchers have uncovered a new way in which a cell protein protects cancer cells from a wide range of chemotherapeutic drugs, identifying a possible target for improving treatment outcomes for patients.
A team of scientists at Children's Cancer Institute Australia for Medical Research (CCIA), led by Associate Professor Maria Kavallaris, discovered that the bIII-tubulin component of the cell's cytoskeleton could play an important role in resistance to a wide range of drugs used to treat lung, ovarian and breast cancers.
Advanced non-small cell lung carcinomas (NSCLC) account for more than 80 per cent of lung cancer cases. More than one million people are diagnosed with lung cancer every year, the most common cancer in the world and the leading cause of cancer deaths. Chemotherapy remains the most effective treatment option, involving a diverse range of drugs, often used in combination. However, the emergence of drug-resistant tumours in NSCLC means chemotherapy no longer holds the promise of a good outcome for many patients.
Increased expression of bIII-tubulin has been linked to drug resistance in NSCLC, ovarian and breast cancers. In the latest Cancer Research publication, Associate Professor Kavallaris and her team showed that blocking the expression of the bIII-tubulin gene in NSCLC cells led to an increase in their sensitivity to a range of chemotherapeutic drugs.
"Our results strongly suggest that the bIII-tubulin component is responsible for protecting NSCLC cells from the action of key chemotherapeutic drugs," said Associate Professor Kavallaris.
"This is the first scientific evidence for the broader implications of abnormal expression of this protein.
"We now have new insight into a mechanism of drug resistance in NSCLC which has not previously been reported. This has important implications for improving the targeting and treatment of a number of cancers which are resistant to current chemotherapeutic drugs," said Associate Professor Kavallaris.
Research Australia
Increased expression of bIII-tubulin has been linked to drug resistance in NSCLC, ovarian and breast cancers. In the latest Cancer Research publication, Associate Professor Kavallaris and her team showed that blocking the expression of the bIII-tubulin gene in NSCLC cells led to an increase in their sensitivity to a range of chemotherapeutic drugs.
"Our results strongly suggest that the bIII-tubulin component is responsible for protecting NSCLC cells from the action of key chemotherapeutic drugs," said Associate Professor Kavallaris.
"This is the first scientific evidence for the broader implications of abnormal expression of this protein.
"We now have new insight into a mechanism of drug resistance in NSCLC which has not previously been reported. This has important implications for improving the targeting and treatment of a number of cancers which are resistant to current chemotherapeutic drugs," said Associate Professor Kavallaris.
Research Australia
Chemotherapeutic Drug Current Events and Chemotherapeutic Drug News RSSPancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.
NIH study reveals new genetic culprit in deadly skin cancer
Drawing on the power of DNA sequencing, National Institutes of Health researchers have identified a new group of genetic mutations involved in the deadliest form of skin cancer, melanoma.
Natural compounds, chemotherapeutic drugs may become partners in cancer therapy
Research in the Linus Pauling Institute at Oregon State University suggests that some natural food compounds, which previously have been studied for their ability to prevent cancer, may be able to play a more significant role in treating it - working side-by-side with the conventional drugs that are now used in chemotherapy.
First compound that specifically kills cancer stem cells found
The cancer stem cells that drive tumor growth and resist chemotherapies and radiation treatments that kill other cancer cells aren't invincible after all.
Anti-psychotic drugs could help fight cancer
The observation that people taking medication for schizophrenia have lower cancer rates than other people has prompted new research revealing that anti-psychotic drugs could help treat some major cancers.
Sensitizing tumor response to cancer therapy
Two forms of skin and brain cancer respond very poorly to chemotherapy and radiation: melanoma and glioblastoma multiforme brain cancer.
Survival predictors may help customize treatment options for men with metastatic prostate cancer
Four risk factors that help predict how long men may survive with metastatic prostate cancer could help doctors choose more effective treatments, according to a study led by researchers in the Duke Comprehensive Cancer Center.
Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers
The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center.
A safe, well-tolerated, and effective treatment for metastatic esophageal cancer
Metastatic esophageal squamous cell cancer has very poor prognosis. Conventional surgery is considered the most effective treatment, but many cases are inoperable at the time of diagnosis.
USC study finds that green tea blocks benefits of cancer drug
Contrary to popular assumptions about the health benefits of green tea, researchers at the University of Southern California (USC) have found that the widely used supplement renders a cancer drug used to treat multiple myeloma and mantle cell lymphoma completely ineffective in treating cancer.
More Chemotherapeutic Drug Current Events and Chemotherapeutic Drug News Articles
 |
Anti-apoptotic and Pro-inflammatory Signaling in Cancer Cells: Status and Modulation by Chemotherapeutic Drugs by Dr. Gabriele Imre (Author) The transcription factor nuclear factor kappa-B (NFkB) plays a pivotal role in the immune response but is also involved in cancer development and progression. In unstimulated cells NFkB is kept inactive in the cytoplasm by inhibitor of NFkB (IkB) proteins. Dysregulation of the pathway or activation of NFkB by chemotherapeutic agents may lead to cancer progression or drug resistance. The NFkB activation status was investigated in human lung cancer, pancreatic cancer, and hematopoietic cancer cell lines. Additionally, the potential of cytotoxic drugs in activating the NFkB signaling pathway was analyzed. Furthermore, the influence of histone deacetylase inhibitors (HDIs) on the NFkB pathway in human non-small cell lung cancer (NSCLC) cell lines was investigated. Incubation of NSCLC cells... |
 |
Burger's Medicinal Chemistry and Drug Discovery, Chemotherapeutic Agents (Volume 5) by Donald J. Abraham (Editor) This is Volume 5: Chemotherapeutic Agents, of Burger's Medicinal Chemistry and Drug Discovery, 6th Edition. This new volume contains critical new chapters on Molecular Biology of Cancer, Synthetic Anti-angiogenic Agents and Selective Toxicities. To purchase the entire 6 volume set, please refer to ISBN 0-471-37032-0. |
|
Transition Metal Complexes as Drugs and Chemotherapeutic Agents (Catalysis by Metal Complexes) by N. Farrell (Author) | |
|
CHEMOTHERAPEUTIC DRUG COMPATIBILITY by Abbott Laboratories Hospital Products Division (Author) | |
 |
Glioblastoma Treatment with 2,5-Dimethyl-Celecoxib (DMC) In Vitro: Effects of Additional Chemotherapeutic Drugs and Tumor Microenvironment - Inconsistencies ... In Vitro Cell Growth and Survival Assays by Nathaniel Soriano (Author) 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex®) that lacks COX-2 inhibitory function yet maintains all of celecoxibs anti-tumor properties. We set out to investigate the potential of combining current glioblastoma chemotherapies with DMC as a new approach to enhance glioblastoma cell killing. DMC was not only able to enhance tumor cell killing when combined with other drugs but also induced glioblastoma growth arrest and apoptosis in low glucose and hypoxic conditions which are normally associated with chemoresistance. Therefore, if DMC were used in combination it may potentially be able to reverse this chemoresistance and restore or even enhance these drugs inhibitory effects. In addition, we also... |
|
Acquired Resistance of Microorganisms to Chemotherapeutic Drugs (Primates in Medicine) by F. E. Hahn (Other Contributor) | |
|
Ionic interpretation of drug action in chemotherapeutic research by Alexander Vladimir Tolstoouhov (Author) | |
 |
Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy (Cancer Drug Discovery and Development) by Benjamin Bonavida (Author), Benjamin Bonavida (Editor) Cancer chemotherapy can be traced back to the 1940 s and since then the world has witnessed the discovery and the important application of several new drugs. The successes of combination chemotherapy suggested that all cancers can be treated provided that the correct combination of drugs at the correct doses and correct intervals are established. However, with time, tumor cells develop mechanisms of resistance to apoptosis and no longer respond to the majority of cytotoxic therapies. Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy, edited by Benjamin Bonavida, reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. Such sensitizing agents target gene... |
|
Sensitivity of Naegleria Fowleri to selected chemotherapeutic drugs (Northeast Louisiana University, Monroe. Master's theses) by Katherine Marie Parker (Author) | |
|
CHEMOTHERAPEUTIC DRUG COMPATIBILITY by Abbott Laboratories (Publisher) |
| © 2009 BrightSurf.com |